- Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer: A multicentre, open-label, randomized phase III studyLu, S.; Zhou, J.; Jian, H.; Wu, L.; Cheng, Y.; Fan, Y.; Fang, J.; Chen, G.; Zhang, Z.; Lv, D.; Jiang, L.; Wu, R.; Jin, X.; Zhang, X.; Zhang, J.; Sun, G.; Huang, D.; Cui, J.; Guo, R.; Ding, L.ESMO Asia Congress, Singapore, SINGAPORE, 2022-12-02 To 2022-12-04.
- A Phase 2 Study of Befotertinib in Patients with EGFR T790M Mutated NSCLC after Prior EGFR TKIsLu, S.; Zhang, Y.; Zhang, G.; Zhou, J.; Cang, S.; Cheng, Y.; Wu, G.; Cao, P.; Lv, D.; Jian, H.; Chen, C.; Jin, X.; Tian, P.; Wang, K.; Jiang, G.; Chen, G.; Chen, Q.; Zhao, H.; Ding, C.; Guo, R.; Sun, G.; Wang, B.; Jiang, L.; Liu, Z.; Fang, J.; Yang, J.; Zhuang, W.; Liu, Y.; Zhang, J.; Pan, Y.; Chen, J.; Yu, Q.; Zhao, M.; Cui, J.; Li, D.; Yi, T.; Yu, Z.; Yang, Y.; Zhang, Y.; Zhi, X.; Huang, Y.; Wu, R.; Chen, L.; Zang, A.; Cao, L.; Li, Q.; Li, X.; Song, Y.; Wang, D.; Zhang, S.
- Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFR T790M-Mutated NSCLC That Had Progressed After Prior EGFR Tyrosine Kinase Inhibitor Therapy: A Phase 2, Multicenter, Single-Arm, Open-Label StudyLu, Shun; Zhang, Yiping; Zhang, Guojun; Zhou, Jianying; Cang, Shundong; Cheng, Ying; Wu, Gang; Cao, Peiguo; Lv, Dongqing; Jian, Hong; Chen, Chengshui; Jin, Xiangming; Tian, Panwen; Wang, Kai; Jiang, Guanming; Chen, Gongyan; Chen, Qun; Zhao, Hui; Ding, Cuimin; Guo, Renhua; Sun, Guoping; Wang, Bin; Jiang, Liyan; Liu, Zhe; Fang, Jian; Yang, Junquan; Zhuang, Wu; Liu, Yunpeng; Zhang, Jian; Pan, Yueyin; Chen, Jun; Yu, Qitao; Zhao, Min; Cui, Jiuwei; Li, Dianming; Yi, Tienan; Yu, Zhuang; Yang, YanJournal of Thoracic Oncology, 2022, 17(10): 1192-1204.被引 7
会议论文
Final overall survival (OS) results of befotertinib in patients with pretreated EGFR T790M-positive locally advanced or metastatic non-small cell lung cancer (NSCLC)
5阅读
